A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts



October 2020 to May 2021

Presentations and panel discussions 1-3 available online

Communication training workshop early-mid career African researchers
working in HIV vaccine research and development

The workshop will focus on written and oral communication to a lay audience, and communication with the mainstream media.

June 2021

Apply by 15 May 2021


How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.

Upcoming event

Enterprise – Communication Training Workshop 2021 (announcement)

The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.


Sign up to receive the latest news of the Vaccine Enterprise and occasional information related to IAS activities related to vaccine research and development (Please read our Privacy Policy)

WP Twitter Auto Publish Powered By : XYZScripts.com